Related Experiment Video
Updated: Jun 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
[Study of mutations causing hypertrophic cardiomyopathy in a group of patients from Espirito Santo, Brazil]
Júlia Daher Carneiro Marsiglia1, Maria do Carmo Pimentel Batitucci, Flávia de Paula
1Universidade Federal do Espírito Santo, Vitória, ES, Brasil. marsigliajdc@yahoo.com.br
Insights
Genetic testing for hypertrophic cardiomyopathy (HC) is feasible in Brazil. Researchers identified two mutations, one potentially pathogenic in the MYBPC3 gene, contributing to understanding HC in the Brazilian population.
Area of Science:
- Genetics
- Cardiology
- Molecular Biology
Context:
- Hypertrophic cardiomyopathy (HC) is a primary genetic heart disease.
- Over 430 mutations identified globally, but none reported in Brazil.
- Need for local genetic studies to understand HC prevalence and causes.
Purpose:
- To conduct a genetic study identifying mutations causing HC in Brazilian patients.
- Investigate specific genes: MYH7, MYBPC3, and TNNT2.
- Utilize Single-Strand Conformation Polymorphism (SSCP) for mutation detection.
Summary:
- 16 alterations found, including two mutations: MYBPC3 (p.Glu441Lys, possibly pathogenic) and TNNT2 (p.Arg92Trp, pathogenic).
- Also identified 8 rare sequence variations and 6 polymorphisms.
- Genotyping patients in Brazil is confirmed as feasible.
Impact:
- Identified potentially pathogenic MYBPC3 variant (p.Glu441Lys) possibly linked to milder HC phenotypes.
- The TNNT2 variant (p.Arg92Trp) showed a less homogeneous phenotype than previously described, potentially causing severe hypertrophy.
- Establishes the foundation for genetic diagnostics and research of HC in Brazil.
Background:
Hypertrophic cardiomyopathy (HC) is the most frequent cardiac hereditary disease, caused by mutations in sarcomere protein coding genes. Although more than 430 mutations have been identified in several continents and countries, there have been no reports of mutations in Brazil.
Objective:
To carry out a genetic study to identify genetic mutations that cause HC in a group of patients in Espirito Santo, Brazil.
Methods:
Using the SSCP technique, 12 exons from the three main genes involved in HC were studied: exons 15, 20, 21, 22 and 23 of the beta-myosin heavy chain gene (MYH7), exons 7, 16, 18, 22 and 24 of the myosin binding protein C gene (MYBPC3) and exons 8 and 9 of troponin T gene (TNNT2).
Results:
16 alterations were found, including two mutations, one of them possibly pathogenic in the MYBPC3 gene (p. Glu441Lys) and another pathogenic one, previously described in the TNNT2 gene (p.Arg92Trp), 8 rare sequence variations and 6 sequence variations with allelic frequency higher than 1% (polymorphisms).
Conclusion:
These data allow the conclusion that the genotyping of patients is feasible in our country. It is possible that the isolated p.Glu441Lys variant identified in exon 16 of the MYBPC3 gene is pathogenic, promoting a milder phenotype than that found when in association with other mutations. The p.Arg92Trp variant in the exon 9 of TNNT2 gene does not promote such a homogeneous phenotype as previously described and it can lead to severe hypertrophy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

